Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IV Infusion of Autologous Adipose Derived Mesenchymal Cells for Abatement of Respiratory Compromise in SARS-CoV-2 Pandemic (COVID-19)

NCT04352803 is registered in ClinicalTrials.gov with Regeneris Medical as lead sponsor.

NCT NCT04352803
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04352803 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IV Infusion of Autologous Adipose Derived Mesenchymal Cells for Abatement of Respiratory Compromise in SARS-CoV-2 Pandemic (COVID-19)
Lead sponsor
Regeneris Medical
Phase
Phase 1
Overall status
Unknown status
Start date
April 30, 2020
Completion date
April 30, 2026
Enrollment
20 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19 pneumonia, cyotokine storm